ArticleFrontiers in neurology2025
Evaluation of the effect of statin treatment on intracranial atherosclerotic plaques using magnetic resonance vessel wall imaging: a case series.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intracranial artery stenosis highly increases the recurrence risk of transient ischemic attack and ischemic stroke, especially in Chinese patients. Patients with intracranial atherrotic disease (ICAD) should be actively treated with risk factor control, such as lipid management. This report discusses vessel wall MRI (VW-MRI) to evaluate plaque in-situ changes in four patients with ICAD after anti-lipid therapy of statins. Case report: Four patients with ischemic stroke and ICAD were prospectively enrolled. VW-MRI and serum low-density lipoprotein cholesterol (LDL-C) were assessed at baseline and follow-up (at least 11-12 months). All patients received statins throughout the study. Compared with baseline, the LDL-C decreased in one case, the length of basilar artery plaque and the overall plaque enhancement segment were shortened, and the plaque thickness was reduced, indicating that the plaque tended to regress. In the second case, LDL-C increased after one year compared with baseline, along with upgraded plaque enhancement and new intraplaque hemorrhage, indicating plaque progression. After 2.5 years, LDL-C decreased significantly, while VW-MRI changes were minimal. LDL-C increased in the third case, but VW-MRI indicated plaque regression. In the fourth case, LDL-C decreased significantly, and the degree of basilar artery plaque stenosis was reduced. However, plaque enhancement upgraded, and intraplaque hemorrhage increased, indicating plaque progression. Conclusion: VW-MRI can monitor the in-situ changes of plaques after lipid-lowering therapy with statins, provide key information that is difficult to reflect in systemic serological lipid indices like LDL-C, and help identify cases that are not responsive to current anti-lipid therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.